Acute Kidney Injury Associated With Semaglutide.
Kidney Med · 2021
Last updated 2026-05-28Two patients with existing kidney disease experienced rapid worsening of kidney function and increased protein in their urine after starting the GLP-1 drug semaglutide. One patient’s kidney tissue showed signs of both long-term damage and new injury. The long-term effects of such kidney problems are not yet known, and the authors suggest caution when using these drugs in people with moderate to severe kidney disease.
AI summary of the abstract below.
| Journal | Kidney Med, 2021 |
|---|---|
| Citations | 41 |
| Relative citation ratio | 2.85 |
| NIH percentile | 83 |
| Molecules | semaglutide |
| Conditions studied | Chronic Kidney Disease |
Abstract
Case reports of acute kidney injury in patients taking the glucagon-like peptide 1 (GLP-1) receptor agonists exenatide and liraglutide have been reported. We report 2 patients with chronic kidney disease due to diabetic kidney disease who experienced rapid worsening of kidney function and increased proteinuria after being prescribed the GLP-1 receptor agonist semaglutide. In 1 patient, kidney biopsy showed advanced diffuse and nodular glomerulosclerosis accompanied by interstitial lymphoplasmacytic and eosinophilic infiltrate and evidence of acute tubular injury. At this time, the long-term outcomes of patients who experience acute kidney injury associated with GLP-1 receptor agonists is not known. We recommend that caution be used with these agents in patients with moderate to severe chronic kidney disease due to limited kidney reserve in the event of an adverse kidney event. Because most adverse kidney events have occurred in patients who experience adverse gastrointestinal symptoms, such patients should have laboratory tests and discontinuation of the medication if there is acute worsening of kidney function.
Verbatim abstract via PubMed 33851124 ↗
Related research
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
- Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.